SciClone Pharmaceuticals, Inc announced promising results from its proof-of-concept phase-2 clinical trial using its proprietary, immunomodulatory compound SCV-07 as a sole agent administered to patients chronically infected with the hepatitis C virus (HCV).
The details can be read here.
No comments:
Post a Comment